high5immunology.tv | Rheumatology | ACR 2021

 This information is brought to you by high5immunology.TV and is not sponsored by, nor a part of, the American College of Rheumatology. 

Spotlight Discussions

DISCOVER 1&2, PSUMMIT

ACR 2021

axPsA is axSpA is not...!?

A. Askari, F. Behrens, P. Sewerin, V. Goeb, E. Lubrano, X. Michelena Vegas

ORAL Surveillance

ACR 2021

Dear Doctor: JAKi risk factors and safety profile - is…

E. Choy, P. Sewerin, F. Behrens, T. Kvien, A. Balsa, A. Rubbert-Roth

MUST

ACR 2021

No need for methotrexate in ustekinumab treatment in…

A. Askari, F. Behrens, P. Sewerin, V. Goeb, E. Lubrano, X. Michelena Vegas

TRAIL1

ACR 2021

Pulmonary involvement and possible therapy concepts in…

E. Choy, P. Sewerin, F. Behrens, T. Kvien, A. Balsa, A. Rubbert-Roth

SPIRIT-H2H

ACR 2021

IL-17 pathway important for pain in PsA

A. Askari, F. Behrens, P. Sewerin, V. Goeb, E. Lubrano, X. Michelena Vegas

ARIAA

ACR 2021

ARIAA: prevention study or very early treatment of RA?

E. Choy, P. Sewerin, F. Behrens, T. Kvien, A. Balsa, A. Rubbert-Roth

TitAIN

ACR 2021

New treatment alternative in GCA: promising secukinumab…

E. Choy, P. Sewerin, F. Behrens, T. Kvien, A. Balsa, A. Rubbert-Roth

Rheumatoid arthritis – ENG

N3C, REDO

ACR 2021

Should we use ultra-low-dose rituximab during the…

Ernest Choy, MD

ORAL Surveillance

ACR 2021

Long awaited - MACE data from ORAL surveillance

Andrea Rubbert-Roth, MD

ARIAA

ACR 2021

Abatacept may reduce subclinical inflammation in RA-at…

Alejandro Balsa, MD, PhD

ORAL Surveillance, National VA registry (U.S.)

ACR 2021

Cardiovascular disease in RA

Ernest Choy, MD

ACR 2021

We need predictors of response for RA treatment

Vincent Goeb, MD, PhD

ACR 2021

Discordance between patients and physicians in RA

Vincent Goeb, MD, PhD

RAMS

ACR 2021

Nausea & alopecia with MTX in RA

Vincent Goeb, MD, PhD

JAK-pot

ACR 2021

Cycling JAKi compared to switching to biologic DMARD in…

Tore Kvien, MD

ACR 2021

Statins reduce cardiovascular risk and​ mortality -…

Alejandro Balsa, MD, PhD

ORAL Surveillance

ACR 2021

Tofacitinib is associated with a slightly increased…

Alejandro Balsa, MD, PhD

Rheumatoid arthritis – FRA/GER/ESP/NOR

ARIAA

ACR 2021

Abatacept reduce la inflamación subclínica en pacientes…

Alejandro Balsa, MD, PhD

ORAL Surveillance

ACR 2021

Tofacitinid se asocia con un ligero incremento del…

Alejandro Balsa, MD, PhD

ACR 2021

Quels marqueurs de réponse aux traitements dans la…

Vincent Goeb, MD, PhD

RAMS

ACR 2021

Quels effets indésirables peuvent être associés à la…

Vincent Goeb, MD, PhD

JAK-pot

ACR 2021

Skifte mellom JAK hemmere sammenliknet med skifte til…

Tore Kvien, MD

ACR 2021

Désaccords patient/Médecin : se comprendre pour plus…

Vincent Goeb, MD, PhD

ORAL Surveillance

ACR 2021

Lange erwartet - MACE-Daten zur ORAL Surveillance

Andrea Rubbert-Roth, MD

ACR 2021

Las estatinas reducen el riesgo cardiovascular y la…

Alejandro Balsa, MD, PhD

Psoriatic arthritis – ENG

SELECT-PsA 1

ACR 2021

Comparison of composit indices for disease activity in…

Ennio Lubrano, MD, PhD

ACR 2021

Secukinumab vs TNF-α blockers in enthesitis

Philipp Sewerin, MD

ACR 2021

Association of C-reactive protein and non-steroidal…

Francesco Ciccia, MD, PhD

MAXIMISE

ACR 2021

Axial PsA MRI data

Xabier Michelena Vegas, MD

MUST

ACR 2021

No need for MTX in ustekinumab-treated patients

Frank Behrens, MD

ACR 2021

Joint effusions and enthesitis after physical exertion

Philipp Sewerin, MD

ACR 2021

Tildrakizumab in PsA

Philipp Sewerin, MD

ACR 2021

Prediction of psoriatic arthritis in patients with…

Francesco Ciccia, MD, PhD

ACR 2021

PET/CT in diagnosis for PsA

Philipp Sewerin, MD

DISCOVER 1&2, PSUMMIT

ACR 2021

Guselkumab: the better ustekinumab?!

Frank Behrens, MD

SPIRIT-H2H

ACR 2021

Pain differs: Superior effect of IL-17-inhibition vs.…

Frank Behrens, MD

DISCOVER 1&2

ACR 2021

Guselkumab in axial symptoms

Philipp Sewerin, MD

DISCOVER 1&2

ACR 20221

Anemia is an issue in PsA - proper treatment possible!

Frank Behrens, MD

Select PsA 1 und 2

ACR 2021

Upadacitinib in PsA

Philipp Sewerin, MD

ACR 2021

Osteoporosis in PsA

Philipp Sewerin, MD

Psoriatic arthritis – GER/ESP/ITA

ACR 2021

Previsione di sviluppo di artrite psoriasica in…

Francesco Ciccia, MD, PhD

ACR 2021

Secukinumab vs TNF-α Blocker bei Enthesitis

Philipp Sewerin, MD

SPIRIT-H2H

ACR 2021

Schmerz ist nicht gleich Schmerz: Unterschied von…

Frank Behrens, MD

DISCOVER 1&2

ACR 2021

Guselkumab bei axialer Symptomatik

Philipp Sewerin, MD

MUST

ACR 2021

Kein Hinweis auf Vorteil einer MTX-Kombi zu Ustekinumab

Frank Behrens, MD

ACR 2021

Gelenkergüsse und Enthesitis nach körperlicher…

Philipp Sewerin, MD

ACR 2021

Associazione di livelli di PCR e uso di FANS con gli…

Francesco Ciccia, MD, PhD

SELECT-PsA 1

ACR 2021

Studio di confronto tra i vari indici compositi per la…

Ennio Lubrano, MD, PhD

ACR 2021

PET-CT zur Quantifizierung der Entzündung

Philipp Sewerin, MD

ACR 2021

Tildrakizumab bei PsA

Philipp Sewerin, MD

DISCOVER 1&2, PSUMMIT

ACR 2021

Guselkumab: das bessere Ustekinumab?!

Frank Behrens, MD

ACR 2021

Osteoporose bei PsA

Philipp Sewerin, MD

Select PsA 1 und 2

ACR 2021

Upadacitinib bei PsA

Philipp Sewerin, MD

DISCOVER 1&2

ACR 2021

Anämie bei PsA ist ein Thema - effektive Therapie…

Frank Behrens, MD

MAXIMISE

ACR 2021

Datos de RM en APs axial

Xabier Michelena Vegas, MD

Axial Spondyloarthritis – ENG

SELECT-AXIS 1

ACR 2021

JAK inhibitors - new kids on the block

Xabier Michelena Vegas, MD

ACR 2021

Dose tapering of TNF inhibitors in axSpA

Xabier Michelena Vegas, MD

MAXIMISE

ACR 2021

Axial PsA MRI data

Xabier Michelena Vegas, MD

ACR 2021

Self-monitoring of disease activity with a smartphone…

Francesco Ciccia, MD, PhD

Axial Spondyloarthritis – ESP/ITA

ACR 2021

l’auto-monitoraggio di malattia è fattibile nella…

Francesco Ciccia, MD, PhD

SELECT-AXIS 1

ACR 2021

Inhibidores JAK: nuevas dianas en EspAax

Xabier Michelena Vegas, MD

MAXIMISE

ACR 2021

Datos de RM en APs axial

Xabier Michelena Vegas, MD

ACR 2021

Optimización de iTNF en EspAax

Xabier Michelena Vegas, MD

Lupus erythematosus – ENG

ACR 2021

JAKi baricitinib successfully mastered phase II study

Bimba Franziska Hoyer, MD

BLISS-BELIEVE

ACR 2021

Not yet a new standard: belimumab + rituximab

Bimba Franziska Hoyer, MD

Lupus erythematosus – GER

BLISS-BELIEVE

ACR 2021

Kombination Belimumab und Rituximab noch kein neuer…

Bimba Franziska Hoyer, MD

ACR 2021

JAK-Inhibitor Baricitinib in Phase II erfolgreich

Bimba Franziska Hoyer, MD

Vasculitis – ENG

TitAIN

ACR 2021

Secukinumab in giant cell arteritis

Carlo Salvarani, MD

TitAIN

ACR 2021

A new therapeutic approach for giant cell arteritis?

Andrea Rubbert-Roth, MD

ACR 2021

PET as a predictor of vascular damage in large-vessel…

Carlo Salvarani, MD

ACR 2021

Baricitinib in relapsing giant cell arteritis

Carlo Salvarani, MD

Vasculitis – GER/ITA

TitAIN

ACR 2021

Secukinumab nell'arterite a cellule giganti

Carlo Salvarani, MD

TitAIN

ACR 2021

Neuer Therapieansatz für die Riesenzellarteriitis?

Andrea Rubbert-Roth, MD

ACR 2021

Baricitinib nell'arterite a cellule giganti recidivante

Carlo Salvarani, MD

ACR 2021

Il ruolo della PET nel predire il danno vascolare nelle…

Carlo Salvarani, MD

COVID-19 – ENG

N3C Registry

ACR 2021

Breakthrough infections after SARS-CoV2-vaccination -…

Bimba Franziska Hoyer, MD

SCQM Registry

ACR 2021

TNF blockers reduce the antibody response to RNA…

Bimba Franziska Hoyer, MD

COVID-19 Global Rheumatology Alliance registry

ACR 2021

Breakthrough infections after SARS-CoV2-vaccination -…

Bimba Franziska Hoyer, MD

N3C, REDO

ACR 2021

Should we use ultra-low-dose rituximab during the…

Ernest Choy, MD

ACR 2021

Vaccination against Delta variant worse in patients…

Bimba Franziska Hoyer, MD

ACR 2021

Booster with which one if there is no seroconversion?

Bimba Franziska Hoyer, MD

ACR 2021

Immune responses to COVID-19 vaccines

Tore Kvien, MD

ACR 2021

Impact of COVID-19 on patients with rheumatic diseases

Ayman Askari, MD

ACR 2021

Anticytokine antibodies causing severe microbacterial…

Ayman Askari, MD

ACR 2021

Analysis of COVID-19 infection among vaccinated…

Ayman Askari, MD

COVID-19 – GER/NOR

SCQM Register

ACR 2021

TNF-Blocker reduzieren Antikörperantwort bei…

Bimba Franziska Hoyer, MD

COVID-19 Global Rheumatology Alliance registry

ACR 2021

Durchbruchsinfektionen nach SARS-CoV2-Impfung -…

Bimba Franziska Hoyer, MD

ACR 2021

Immunresponser til COVID-19 vaksiner

Tore Kvien, MD

N3C Register

ACR 2021

Durchbruchsinfektionen nach SARS-CoV2-Impfung -…

Bimba Franziska Hoyer, MD

ACR 2021

Womit boostern bei fehlender Serokonversion?

Bimba Franziska Hoyer, MD

ACR 2021

Schlechtere Neutralisation der Delta-Variante unter…

Bimba Franziska Hoyer, MD

Varia – ENG

VITAL

ACR 2021

New exciting data - dietary supplements with vitamin D…

Andrea Rubbert-Roth, MD

ACR 2021

Pearls and myths in rheumatology

Ayman Askari, MD

COMPACT

ACR 2021

PROs from a real-world study on etanercept biosimilar -…

Ayman Askari, MD

ACR 2021

CBD - an alternative therapy for chronic pain

Ayman Askari, MD

ACR 2021

Skin findings in patients of color with rheumatic…

Ayman Askari, MD

NOR-DRUM B

ACR 2021

Therapeutic drug monitoring - a randomized controlled…

Tore Kvien, MD

Varia – GER/NOR

VITAL

ACR 2021

Neue spannende Daten - Nahrungsergänzung mit Vitamin D…

Andrea Rubbert-Roth, MD

NOR-DRUM B

ACR 2021

Monitorering av legemiddelkonsentrasjoner (Therapeutic…

Tore Kvien, MD